Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT03210935
Recruiting Observational

French National Database of Rare Dermatological Cancers

NCT03210935 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Lille
Phase
Observational
Started
2015-11-24
Last updated
2026-05-22

Condition(s) studied

Adnexal Tumor of SkinMerkel Cell CarcinomaAdvanced Basal Cell Carcinoma Requiring Systemic Treatment

Study summary

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes.

CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are :

* to provide epidemiological, clinical and socio-economic characteristics of patients
* to identify new clinical or epidemiological prognostic factors for these rare cancers
* to evaluate the impact of various treatments on outcomes

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma Exclusion Criteria: * Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma * Patients refusal

Primary outcome measure(s)

  • Incidence and natural history of the 3 types of rare skin cancers — 10 years

Trial sites (34)

FacilityCityRegionStatus
CHU Bocage Dijon Dijon Recruiting
CH Le Mans Le Mans Le Mans Recruiting
Centre hospitalier Lyon Sud Pierre-Bénite Pierre-benite Recruiting
CHU Amiens Picardie Amiens France Recruiting
CHU Angers Angers France Recruiting
CH Annecy Gennevois Annecy France Recruiting
CHU Besançon Besançon France Recruiting
CHU Avicenne Bobigny France Recruiting
CHU Ambroise Paré Boulogne-Billancourt France Recruiting
CHU de Brest Brest France Recruiting
CHU de Caen Caen France Recruiting
CHU de Clermont Ferrand Clermont-Ferrand France Recruiting
CHU de Grenoble Grenoble France Recruiting
CHU de Limoges Limoges France Recruiting
Centre Léon Bérard Lyon France Recruiting
Hôpital La Timone Marseille France Recruiting
Hôpital St Eloi Montpellier France Recruiting
CHU de Nancy Nancy France Recruiting
CHU Nantes - Place Alexis Ricordeau Nantes France Recruiting
CHU de Nice Nice France Recruiting
CHR d'Orleans Orléans France Recruiting
CHU Bichat Paris France Recruiting
CHU Cochin Paris France Recruiting
CHU St Louis Paris France Recruiting
CHU de Bordeaux Pessac France Recruiting
CHU de Pointe à Pitre Pointe à Pitre France Recruiting
CHU de Poitiers Poitiers France Recruiting
CHU de Reims Reims France Recruiting
CHU de Rennes Rennes France Recruiting
CHU de Rouen Rouen France Recruiting
CHU de Strasbourg Strasbourg France Recruiting
CHU de Toulouse - Larrey Toulouse France Recruiting
CHU de Tours Tours France Recruiting
Institut Gustave Roussy Villejuif France Recruiting

More University Hospital, Lille trials in France

Antibiotic Strategy and Asymptomatic Bacteriuria in the Context of Intra-vesical Botulinum Toxin A Injections. Starting soon
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Recruiting
Effectiveness of Erector Spinae Plane Block for Percutaneous Arthrodesis of Spinal Fractures Active, not recruiting
Performance of Carbon Dioxide (CO2)-Derived Parameters in Predicting Low Cardiac Output Syndrome Recruiting
Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss Recruiting

Other trials for the same condition

SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03210935 on ClinicalTrials.gov ↗ ← All trials in France